How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Cancer Diagnostics(Tumor Biomarker Tests, Imaging, Endoscopy And Biopsy) Market
- By Diagnostic Method: Tumor Biomarker Tests, Imaging Techniques, Endoscopy Procedures, Biopsy Techniques
- By Imaging Technique Type: Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, Positron Emission Tomography (PET), Ultrasound Imaging, X-ray Imaging
- By Tumor Biomarker Test Type: Protein Biomarker Tests, Genetic Biomarker Tests, Circulating Tumor DNA (ctDNA) Tests, Immunohistochemistry (IHC) Tests, Enzyme-Linked Immunosorbent Assay (ELISA)
- By Endoscopy Type: Colonoscopy, Gastroscopy, Bronchoscopy, Cystoscopy, Laparoscopy
- By Biopsy Technique: Fine Needle Aspiration Biopsy, Core Needle Biopsy, Surgical Biopsy, Liquid Biopsy, Excisional Biopsy
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Tumor Biomarker Tests leads By Diagnostic Method at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Cancer Diagnostics(Tumor Biomarker Tests, Imaging, Endoscopy And Biopsy) Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Diagnostic Method 4
Imaging Technique Type 5
Tumor Biomarker Test Type 5
Endoscopy Type 5
Biopsy Technique 5
Companies profiled
Roche Diagnostics
Abbott Laboratories
Siemens Healthineers
Thermo Fisher Scientific
Becton Dickinson and Company (BD)
Danaher Corporation
Hologic Inc.
Agilent Technologies
Sysmex Corporation
Bio-Rad Laboratories
Fujifilm Holdings Corporation
Olympus Corporation
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Becton Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Danaher Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Hologic Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Agilent Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sysmex Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Bio-Rad Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Fujifilm Holdings Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Olympus Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Canon Medical Systems Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →GE Healthcare
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →PerkinElmer
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,541M by 2033 · 8.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Tumor Biomarker Tests48.6
- Imaging Techniques11.4
- Endoscopy Procedures17.6
- Biopsy Techniques22.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$591.1M → $1,277M · 10.1%
Europe$412.0M → $746.8M · 7.7%
Asia Pacific$376.1M → $670.3M · 7.5%
Latin America$232.8M → $444.2M · 8.4%
Middle East and Africa$179.1M → $392.4M · 10.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.852026
8.872027
8.882028
8.872029
8.902030
8.902031
8.922032
8.922033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche Diagnostics24.7
- Abbott Laboratories12.2
- Siemens Healthineers12.5
- Thermo Fisher Scientific5.3
- Becton Dickinson and Company (BD)11.6
- Danaher Corporation5.6
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Diagnostic Method22.4%
Imaging Technique Type29.6%
Tumor Biomarker Test Type14.7%
Endoscopy Type17.0%
Biopsy Technique16.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.2
- Europe21.2
- Asia Pacific19.0
- Latin America12.6
- Middle East and Africa11.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche Diagnostics | 77 | 86 | 84 | 93 | 99 | 82 | 87 |
| Abbott Laboratories | 83 | 92 | 93 | 92 | 88 | 77 | 88 |
| Siemens Healthineers | 81 | 70 | 79 | 73 | 79 | 83 | 78 |
| Thermo Fisher Scientific | 63 | 76 | 65 | 64 | 67 | 64 | 67 |
| Becton Dickinson and Company (BD) | 54 | 71 | 54 | 64 | 68 | 71 | 64 |
| Danaher Corporation | 62 | 64 | 61 | 70 | 54 | 63 | 62 |
| Hologic Inc. | 64 | 47 | 59 | 51 | 52 | 41 | 52 |
| Agilent Technologies | 37 | 51 | 56 | 54 | 37 | 47 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche Diagnostics
- Abbott Laboratories
- Siemens Healthineers
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche Diagnostics | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Abbott Laboratories | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Siemens Healthineers | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Thermo Fisher Scientific | ◐ | ✓ | − | ◐ | − | ◐ |
| Becton Dickinson and Company (BD) | ◐ | ✓ | − | ◐ | ◐ | ◐ |
| Danaher Corporation | − | − | ◐ | ✓ | − | ◐ |
| Hologic Inc. | ◐ | ◐ | ◐ | − | ◐ | − |
| Agilent Technologies | − | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories88
2Roche Diagnostics87
3Siemens Healthineers78
4Thermo Fisher Scientific67
5Becton Dickinson and Company (BD)64
6Danaher Corporation62
7Hologic Inc.52
8Agilent Technologies47
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Roche DiagnosticsAbbott LaboratoriesSiemens Healthineers
Challenger1
Strong scale, closing on the leaders.
Thermo Fisher Scientific
Contender2
Focused players with pockets of strength.
Becton Dickinson and Company (BD)Danaher Corporation
Niche2
Specialists in a single segment or region.
Hologic Inc.Agilent Technologies
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Diagnostic Method in North America, then scale across Cancer Diagnostics(Tumor Biomarker Tests, Imaging, Endoscopy And Biopsy) Market — a $159M beachhead inside a $2.58B market.
Beachhead (SOM)$159Mobtainable near-term
Serviceable (SAM)$1.05Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Tumor Biomarker Tests
Best fit — highest urgency & budget in Diagnostic Method.
Economic buyer76 fit
Imaging Techniques
Strong fit — clear ROI and a fast path to value.
End user67 fit
Endoscopy Procedures
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Diagnostic Method in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Imaging Technique Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Tumor Biomarker Test Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel26%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Diagnostic Method leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cancer Diagnostics(Tumor Biomarker Tests, Imaging, Endoscopy And Biopsy) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified23%
Evaluation14%
Closed-won6%
$17.7KCAC
$79KLTV
4.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cancer Diagnostics(Tumor Biomarker Tests, Imaging, Endoscopy And Biopsy) Market is a durable-growth opportunity — $4.03B by 2033, compounding at 8.5%.
TAM · 2025$2.10Btoday
TAM · 2033$4.03Bforecast
CAGR8.5%2027–2033
Cumulative$26.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.03BTotal addressable market
SAM$1.60BServiceable available market
SOM$310MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.5% CAGR
Demand compounds through 2033, outpacing GDP across Diagnostic Method.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Diagnostic Method moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.03BLarge & growingTAM by 2033 at 8.5% CAGR
$1.60BServiceable nowreachable with today’s model
$310MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.14BBear5.5% CAGR
$4.03BBase8.5% CAGR
$5.15BBull11.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Imaging Technique Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cancer Diagnostics(Tumor Biomarker Tests, Imaging, Endoscopy And Biopsy) Market — a $5.98B market by 2033. Plan: grow share from 9.7% to 14.9%.
Market size · 2033$5.98Btotal addressable
Market CAGR4.5%2027–2033
Target share14.9%from 9.7% today
Revenue ambition$891Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.7% | 14.9% | At risk |
| Revenue | $628M | $891M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 30.0% | 45.3% | At risk |
| Customer retention | 90.5% | 95.3% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Diagnostic Method
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Imaging Technique Type capability
A defensible second engine — invest in Imaging Technique Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Diagnostic Method share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Imaging Technique Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $130M capacity & capability investment
- Greenlight bolt-on M&A in Imaging Technique Type
- Authorise North America expansion plan
- Fund R&D program for Diagnostic Method leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cancer Diagnostics(Tumor Biomarker Tests, Imaging, Endoscopy And Biopsy) Market conversation — a $1.71B market you can size, segment and defend in minutes.
Market size · 2033$1.71Btotal opportunity
Growth8.0%CAGR to 2033
Addressable buyers1,274+accounts in scope
Typical ROI6.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Diagnostic Method
Goal Grow share in Diagnostic Method
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.6×return on cost, year one
< 4 mopayback period
$68K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Roche DiagnosticsAbbott LaboratoriesSiemens HealthineersThermo Fisher ScientificBecton Dickinson and Company (BD)Danaher CorporationHologic Inc.Agilent Technologies+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cancer Diagnostics(Tumor Biomarker Tests, Imaging, Endoscopy And Biopsy) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cancer Diagnostics(Tumor Biomarker Tests, Imaging, Endoscopy And Biopsy) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cancer Drug Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportCancer Gene Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportCancer Growth Inhibitors Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportCancer Hormone Therapy Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportCancer Immunomodulators Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportCancer Janus Kinase Inhibitor Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportCancer or Tumor Profiling Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportCancer Profiling Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportCancer Research Centers', 'Hospital', 'Others Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportCancer Supportive Care Drug Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportCancer Therapeutics And Biotherapeutic Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportCancer Therapeutics Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.